Vigil Neuroscience

About Vigil Neuroscience

Vigil Neuroscience is a clinical-stage biotechnology company established in 2020 with a focus on neurodegenerative diseases, specifically by targeting microglia, the brain's resident immune cells. The company was co-founded and incubated by Atlas Venture, launching with an initial $50 million Series A financing round with assets in-licensed from Amgen. The founding President and CEO, Dr. Ivana Magovčević-Liebisch, brought extensive industry experience to the firm, having previously held leadership roles at companies like Dyax and serving on the boards of other biotechnology firms. Her background combines a Ph.D. in Genetics from Harvard University with a Juris Doctor degree, providing a foundation in both the scientific and business aspects of biotechnology.

The company's business model is typical of a development-stage biotech firm, centering on substantial investment in research and development to move therapeutic candidates through rigorous clinical trials. Prior to generating revenue from product sales, Vigil Neuroscience raised capital through several financing rounds, including a $90 million Series B in August 2021 and a subsequent Initial Public Offering (IPO) on the Nasdaq exchange on January 7, 2022, which raised $98 million. A significant milestone occurred in May 2025, when Sanofi announced its agreement to acquire Vigil Neuroscience for approximately $470 million. This acquisition, completed in August 2025, was primarily centered on Vigil's small molecule program, VG-3927.

Vigil's therapeutic strategy revolves around activating the TREM2 (Triggering Receptor Expressed on Myeloid cells 2) receptor on microglia to restore their protective function. The company's pipeline included two main candidates. The first, iluzanebart (VGL101), is a fully human monoclonal antibody licensed from Amgen. It was initially developed for Adult-onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP), a rare and fatal genetic neurodegenerative disease. Despite showing promise in early trials, the Phase II IGNITE study for iluzanebart did not meet its endpoints, and the program was discontinued. The second key asset, and the focus of the Sanofi acquisition, is VG-3927, an oral small-molecule TREM2 agonist. This drug is designed for more common neurodegenerative diseases like Alzheimer's, offering the convenience of oral administration and the ability to penetrate the central nervous system effectively. Phase 1 results for VG-3927 in healthy volunteers were positive, demonstrating safety and target engagement, which paved the way for its advancement into Phase 2 trials under Sanofi's direction.